Back to Journals » International Journal of Nanomedicine » Volume 7

MS2 VLP-based delivery of microRNA-146a inhibits autoantibody production in lupus-prone mice

Authors Pan Y, Jia, Zhang, Zhang, Zhang, Li, Wang L

Received 11 September 2012

Accepted for publication 22 October 2012

Published 3 December 2012 Volume 2012:7 Pages 5957—5967


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Yang Pan,1,2 Tingting Jia,1,2 Yuan Zhang,1,2 Kuo Zhang,1 Rui Zhang,1 Jinming Li,1 Lunan Wang1

National Center for Clinical Laboratories, Beijing Hospital of the Ministry of Health, Beijing, People’s Republic of China; 2Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, People’s Republic of China

Background: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the presence of pathogenic autoantibodies. Recent studies suggest that microRNAs (miRNAs) play an essential role in immunoregulation and may be involved in the pathogenesis of SLE. Therefore, it was of interest to investigate the potential therapeutic application of miRNAs in SLE, a concept that has not been thoroughly investigated thus far. Virus-like particles (VLPs) are a type of recombinant nanoparticle enveloped by certain proteins derived from the outer coat of a virus. Herein, we describe a novel miRNA-delivery approach via bacteriophage MS2 VLPs and investigate the therapeutic effects of miR-146a, a well-studied and SLE-related miRNA, in BXSB lupus-prone mice.
Methods: VLPs containing miR-146a, and the control VLPs, were prepared using an Escherichia coli expression system and then administered to lupus-prone mice over a 12-day period. We performed an enzyme-linked immunosorbent assay to evaluate the anti-dsDNA antibody, autoantibody to nuclear antigen (ANA), total IgG and total IgM levels in serum. The expression of miR-146a was analyzed by qRT-PCR. SLE-related cytokines as well as some toll-like receptor signaling pathway molecules were also measured.
Results: Treatment with MS2-miR146a VLP showed profound effects on lupus-prone BXSB mice, including an increased level of mature miR-146a, which led to a significant reduction in the expression of autoantibodies and total IgG. Remarkably, these mice also exhibited reduced levels of proinflammatorycytokines, including IFN-Interferon-α (IFN-α), Interleukin-1β (Il-1β) and Interleukin-6 (Il-6). Moreover, we showed that the toll-like receptor pathway was involved in this regulation.
Conclusion: Restoring the loss of miR-146a was effective in eliminating the production of autoantibodies and ameliorating SLE progression in lupus-prone mice. Thus, the induction of dysregulated miRNAs by an MS2 VLP-based delivery system may lead to novel therapies.

Keywords: systemic lupus erythematosus, anti-dsDNA antibody, autoantibody to nuclear antigen, Toll-like receptor, BXSB mice, gene therapy.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Readers of this article also read:

Enhancing microparticle internalization by nonphagocytic cells through the use of noncovalently conjugated polyethyleneimine

Patiño T, Nogués C, Ibáñez E, Barrios L

International Journal of Nanomedicine 2012, 7:5671-5682

Published Date: 8 November 2012

Functionalized carbon nanotubes: biomedical applications

Vardharajula S, Ali SZ, Tiwari PM, Eroğlu E, Vig K, Dennis VA, Singh SR

International Journal of Nanomedicine 2012, 7:5361-5374

Published Date: 9 October 2012

Liver cell specific targeting by the preS1 domain of hepatitis B virus surface antigen displayed on protein nanocages

Murata M, Narahara S, Umezaki K, Toita R, Tabata S, Piao JS, Abe K, Kang JH, Ohuchida K, Cui L, Hashizume M

International Journal of Nanomedicine 2012, 7:4353-4362

Published Date: 9 August 2012

The scent fingerprint of hepatocarcinoma: in-vitro metastasis prediction with volatile organic compounds (VOCs)

Amal H, Ding L, Liu BB, Tisch U, Xu ZQ, Shi DY, Zhao Y, Chen J, Sun RX, Liu H, Ye SL, Tang ZY, Haick H

International Journal of Nanomedicine 2012, 7:4135-4146

Published Date: 30 July 2012


Marusza W, Mlynarczyk G, Olszanski R, Netsvyetayeva I, Obrowski M, Iannitti T, Palmieri B

International Journal of Nanomedicine 2012, 7:4119-4120

Published Date: 27 July 2012

Lysine-functionalized nanodiamonds: synthesis, physiochemical characterization, and nucleic acid binding studies

Kaur R, Chitanda JM, Michel D, Maley J, Borondics F, Yang P, Verrall RE, Badea I

International Journal of Nanomedicine 2012, 7:3851-3866

Published Date: 19 July 2012

Effect of molecular weight of polyethyleneimine on loading of CpG oligodeoxynucleotides onto flake-shell silica nanoparticles for enhanced TLR9-mediated induction of interferon-α

Manoharan Y, Ji Q, Yamazaki T, Chinnathambi S, Chen S, Ganesan S, Hill JP, Ariga K, Hanagata N

International Journal of Nanomedicine 2012, 7:3625-3635

Published Date: 16 July 2012

NC-6301, a polymeric micelle rationally optimized for effective release of docetaxel, is potent but is less toxic than native docetaxel in vivo

Harada M, Iwata C, Saito H, Ishii K, Hayashi T, Yashiro M, Hirakawa K, Miyazono K, Kato Y, Kano MR

International Journal of Nanomedicine 2012, 7:2713-2727

Published Date: 31 May 2012


Iancu C, Mocan L

International Journal of Nanomedicine 2011, 6:2543-2544

Published Date: 21 October 2011

Multi-access drug delivery network and stability

Mitatha S, Moongfangklang N, Jalil MA, Suwanpayak N, Ali J, Yupapin PP

International Journal of Nanomedicine 2011, 6:1757-1764

Published Date: 23 August 2011